Canon's latest entry into the PET/CT market is a digital, air-cooled system that provides customizable solutions for a range of clients.
As the country--and the world--continues to grapple with the ongoing COVID pandemic, the imaging industry is looking to re-find its footing in an evolving landscape where customized solutions are key to success.
Enter Canon Medical's Cartesion Prime digital PET/CT, introduced in 2019, which provides a high-performance, adaptable system for today's evolving imaging technology. Optimizing both workflow and image quality via advanced silicon photomultiplier design with one-to-one coupling, fast time-of-flight and deep learning reconstruction technology, “this advanced technology has led to image quality improvements, while optimizing dose efficiency to reduce patient risk and speeding up acquisition time for improved throughput," said Tim Nicholson, managing director, Molecular Imaging Business Unit, Canon Medical Systems USA.
In an interview with Diagnostic Imaging, Nicholson expanded on the needs of the industry and how Canon is answering the call.
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.